Sector: Health Care
Director information for JAZZ PHARMACEUTICALS PLC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Anne O’Riordan(1) | [] | ["Compensation Committee","Nominating Committee"] | 2026 | ||
| Bruce C. Cozadd | Chairperson, Jazz Pharmaceuticals plc; Chairperson of the Board; Chairperson and Former CEO; Former PEO | 62 | ["Co-founder of Jazz Pharmaceuticals, Inc.","Former CEO of Jazz Pharmaceuticals, Inc.","Served as Executive Chairperson of Jazz Pharmaceuticals, Inc.","Held various positions at ALZA Corporation including Executive Vice President and COO","Served on the board of ACELYRIN, Inc.","Board member of The Nueva School","Holds a B.S. from Yale University","Holds an M.B.A. from Stanford Graduate School of Business","commercial industry experience","unique knowledge of our business"] | [] | 2026 |
| Heather Ann McSharry | Director, International Consolidated Airlines Group, S.A. | 64 | ["Over 30 years of experience in multiple international industries","Expertise in crisis management","Expertise in risk oversight","Expertise in financial services"] | ["Audit Committee","Compensation Committee","Nominating Committee","Transaction Committee","SMC"] | 2026 |
| Jennifer E. Cook | Director, BridgeBio Pharma, Inc. and Denali Therapeutics Inc.; Non-Executive Director; Member | 60 | ["Over 30 years of biopharmaceutical experience","Significant C-suite experience","Global product development and commercialization expertise","Focus on transformative growth","Founded Jennifer Cook Consulting","Former CEO at GRAIL, Inc.","Worked at Roche Pharmaceuticals/Genentech for 25 years"] | ["Compensation Committee","Audit Committee"] | 2026 |
| Laura J. Hamill | Director, BB Biotech AG | 61 | ["Over 35 years of commercial expertise in the biopharmaceutical industry","Various executive leadership positions in the U.S. and internationally","Former Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc.","Senior Vice President, U.S. Commercial Operations at Amgen Inc.","Consultant for Launch Therapeutics, Inc.","Board member of several biopharmaceutical companies"] | ["Audit Committee","Compensation Committee"] | 2026 |
| Mark D. Smith, M.D. | Professor, University of California, San Francisco and Director, Phreesia, Inc. and Teladoc Health, Inc.; Member | 74 | ["Practicing physician","Professor of clinical medicine at the University of California at San Francisco","Non-executive director on the boards of Teladoc Health, Inc. and Phreesia, Inc.","Founding President and CEO of the California HealthCare Foundation","Executive Vice President at the Henry J. Kaiser Family Foundation","B.A. from Harvard College","M.D. from the University of North Carolina at Chapel Hill","M.B.A. from The Wharton School at the University of Pennsylvania"] | ["Audit Committee","Compensation Committee","Nominating Committee"] | 2026 |
| Neena M. Patil | Executive Vice President and Chief Legal Officer; Non-PEO NEO | 51 | ["Senior Vice President and General Counsel at Jazz Pharmaceuticals","Senior Vice President, General Counsel and Corporate Secretary at Abeona Therapeutics Inc.","Vice President for Legal Affairs and Associate General Counsel at Novo Nordisk Inc.","Board member of Teleflex, Inc."] | ["Nominating and Governance Committee"] | 2026 |
| Norbert G. Riedel, Ph.D. | Chairperson, Eton Pharmaceuticals, Inc.; Chairperson of the Board | 68 | ["over 30 years of experience in the biotechnology and pharmaceutical industries","significant scientific, drug discovery and development, and commercial expertise","Adjunct Professor at Boston University School of Medicine","Adjunct Professor of Medicine at Northwestern University’s Feinberg School of Medicine"] | ["Audit Committee","Compensation Committee","SMC","Nominating Committee"] | 2026 |
| Patrick G. Enright | Managing Director, Longitude Capital and Director, BioAge Labs, Inc., Vera Therapeutics, Inc., Veradermics, Inc. and Zenas BioPharma, Inc. | 64 | ["Experience serving on the boards of several clinical-stage biotechnology companies","Investment experience in the life sciences industry","Operating experience and financial expertise in the life sciences industry","Co-founder of Longitude Capital","Managing Director at Pequot Ventures"] | ["Audit Committee","Compensation Committee"] | 2026 |
| Patrick Kennedy | Director, Jazz Pharmaceuticals plc; Member of the Board | 57 | ["over 30 years of experience","extensive financial and operating expertise","CEO of Paddy Power plc","CFO of Greencore Group plc","experience with KPMG Corporate Finance","experience with McKinsey & Company","non-executive director of Elan Corporation plc","non-executive director of ASOS plc","chair and non-executive director of CarTrawler","Honorary Treasurer of the Irish Rugby Football Union","BComm degree (Banking & Finance) from University College Dublin","Post Graduate Diploma in Accountancy from University College Dublin","Post Graduate Diploma in Statistics from Trinity College Dublin","Fellow of the Institute of Chartered Accountants in Ireland"] | ["Compensation Committee","Audit Committee","Transaction Committee"] | 2026 |
| Philip L. Johnson | Executive Vice President and CFO; Non-PEO NEO | 62 | ["Served as group vice president and treasurer at Eli Lilly and Company","Management consultant at McKinsey & Company","Experience with investment banks in Milan, Italy and Chicago, Illinois","B.S. in Finance from the University of Illinois","MBA from the Kellogg School of Management at Northwestern University"] | ["Executive board member of the Indianapolis Urban League","Board member of Lynx Capital","Advisory committee member for Jumpstart Nova","Advisory committee member for Sixty8 Capital"] | 2026 |
| Renee D. Gala | President and CEO, Jazz Pharmaceuticals plc and Director, Dexcom, Inc.; President and Chief Executive Officer; President, CEO and Director; PEO | 54 | ["More than 30 years of experience across finance, strategy, corporate development, and commercialization.","Previous CFO of GRAIL, Inc.","Senior Vice President and CFO of Theravance Biopharma, Inc.","Held various finance roles at Theravance since 2006.","Experience in corporate finance, project finance, and mergers and acquisitions in the energy industry.","Served on the board of multiple biotech companies."] | [] | 2026 |
| Rick E Winningham | Chief Executive Officer, Theravance Biopharma, Inc.; Lead Independent Director; Member | 66 | ["Experience in senior management positions in the pharmaceuticals industry","Significant industry knowledge","Operational and management expertise","Deep knowledge of global marketing, commercialization and market access"] | ["Audit Committee","Compensation Committee","Nominating Committee"] | 2026 |
| Robert Iannone, M.D., M.S.C.E. | Executive Vice President, Global Head of Research and Development and Chief Medical Officer | 59 | ["B.S. from The Catholic University of America","M.D. from Yale University","M.S.C.E. from University of Pennsylvania","Residency in Pediatrics at Johns Hopkins University","Fellowship in Pediatric Hematology-Oncology at Johns Hopkins University","Board member of Autolus Therapeutics plc since June 2023","Former director at Jounce Therapeutics, Inc. from January 2020 to May 2023","Former director at iTeos Therapeutics, Inc. from May 2021 to August 2025","Previously served roles at Immunomedics, Inc. and AstraZeneca plc"] | ["Cancer Steering Committee of the Foundation for the National Institutes of Health"] | 2026 |
| Seamus C. Mulligan | Director, Jazz Pharmaceuticals plc; Member | 65 | ["Founder of Azur Pharma","Employee of Elan Corporation plc","CEO of Adapt Pharma Limited","Expertise in business development","Over 40 years of experience in the pharmaceutical industry"] | ["Transaction Committee","Nominating Committee"] | 2026 |
| Ted W. Love, M.D. | Director, Gilead Sciences, Inc., Royalty Pharma plc, and Structure Therapeutics Inc.; Member | 67 | ["More than 30 years of biopharmaceutical leadership","Expertise in drug development","Commercialization","Public policy"] | ["Audit Committee","Compensation Committee","Nominating Committee"] | 2026 |
